AI Due Diligence Framework for Healthcare Investments

Table of Contents

1. Why AI Due Diligence Matters in Healthcare
2. The AI Readiness Assessment
3. Technical Architecture & Regulatory Risk
4. Data Quality, Governance & Compliance
5. Model Risk Management & Validation
6. Team, Hiring & Capability Gaps
7. Value-Creation Roadmap: 100-Day Plan
8. Exit Positioning: AI as a Moat
9. Red Flags & Deal-Breakers
10. Next Steps & Implementation

---

Why AI Due Diligence Matters in Healthcare

Healthcare has become ground zero for AI investment. From diagnostic imaging to clinical trial optimisation to revenue cycle automation, the sector is deploying machine learning at scale. But unlike software or fintech deals, healthcare AI carries regulatory complexity that can derail post-acquisition value creation or blow up at exit.

Private equity firms backing healthcare companies face a specific problem: traditional tech due diligence doesn’t catch the risks that matter most. A team that built a slick ML model for patient triage might have no governance framework. A platform processing HIPAA-regulated data might have no audit trail. A diagnostic algorithm trained on a narrow dataset might fail catastrophically in production.

Worse, regulators are watching. The FDA’s oversight of AI/ML software as a medical device has tightened. Clinical AI governance is now table stakes—and many mid-market healthcare companies haven’t built it. By the time you’re in diligence, you need to know whether the target has genuine AI capability or just a prototype that will cost millions to productionise.

This guide gives you the framework. It’s built on hundreds of healthcare tech audits, dozens of post-acquisition AI rollouts, and real benchmarks from exits. It’s written for PE operators and technical advisors who need to separate signal from noise, quantify risk, and spot value-creation opportunities before the deal closes.

---

The AI Readiness Assessment

Start here. Before you dig into model architecture or regulatory compliance, you need a 360-degree view of where the target stands on AI maturity. This isn’t about whether they have AI—it’s about whether their AI is production-ready, scalable, and defensible.

The Five Pillars of AI Readiness

Pillar 1: Strategy & Roadmap Clarity

Ask: What problem does AI solve, and how does it move the revenue needle? Too many healthcare companies deploy AI because it’s trendy, not because it drives economics. A diagnostic imaging vendor might use AI to reduce radiologist time by 20%, but if that doesn’t translate to throughput gain or cost savings, it’s just a feature, not a moat.

Look for specificity. “We use AI for clinical decision support” is vague. “Our AI flags high-risk patients in the ED, reducing unnecessary admissions by 15%, saving $2.1M annually per hospital” is concrete. Quantify the impact: revenue uplift, cost reduction, time saved, or risk mitigated. If the target can’t articulate this in numbers, the AI strategy is probably aspirational.

Also assess the roadmap. Is AI baked into product development, or bolted on? Are there clear milestones for the next 12–24 months? Does the team have conviction, or are they chasing hype? A strong AI roadmap should show phased rollout, measured by clinical outcomes or operational KPIs, not just model accuracy.

Pillar 2: Data Infrastructure & Maturity

AI is only as good as the data feeding it. In healthcare, that’s a high bar. You need clean, labelled, longitudinal data—and most health systems have fragmented EHR silos, inconsistent coding, and poor data governance.

During diligence, map the data estate. Where does training data come from? Is it a single health system (high risk of poor generalisation) or a multi-site network? How much labelled data exists? In clinical AI, you often need thousands of manually annotated examples. If the target has only 500 labelled records for a rare disease, the model won’t generalise.

Check data quality. Are there missing values, duplicates, or coding inconsistencies? Is there a data governance function? Who owns data lineage? In regulated healthcare, you need audit trails—who accessed what data, when, and why. If the answer is “we don’t really track that,” you’ve found a compliance gap that will cost millions to remediate.

Also ask about data freshness. Models trained on 2021 data will drift in production. Is there a pipeline to retrain models with fresh data? How often? Without continuous retraining, model performance degrades, especially in clinical settings where patient populations and disease prevalence shift.

Pillar 3: Model Development & Validation Rigour

Here’s where many healthcare AI projects fail. Teams build models in notebooks, validate them on the same data they trained on, and ship them to production without external validation. In healthcare, that’s not just sloppy—it’s dangerous.

During diligence, ask:

• How were models developed? (Jupyter notebooks in a folder, or version-controlled, reproducible pipelines?)
• How were they validated? (Train/test split, or proper cross-validation and external holdout sets?)
• Has the model been validated by clinicians or domain experts?
• Are there published results, or only internal benchmarks?
• What’s the model’s performance on edge cases—rare diseases, underrepresented populations, edge-case presentations?

For diagnostic models, look for clinical validation studies. If a radiology AI claims 95% sensitivity, ask: on what dataset? How many images? Were they from the target’s own system, or external data? Was there inter-rater agreement with radiologists? Peer-reviewed publications are a strong signal; internal reports are not.

Also check for bias and fairness. Healthcare AI has a documented problem: models trained on predominantly white, male datasets perform worse on women and minorities. Ask whether the target has audited model performance across demographic groups. If not, you’ve found a regulatory and reputational risk.

Pillar 4: Deployment & Monitoring in Production

The gap between “model in development” and “model in production” is where most healthcare AI projects stall. Deployment requires infrastructure, monitoring, retraining pipelines, and fallback procedures.

Ask:

• How many models are in production today? (Be sceptical of “we have 50 models”—most are probably prototypes.)
• What’s the deployment architecture? (Is it integrated into the EHR, or a separate system?)
• How is model performance monitored? (Are there alerts if accuracy drops?)
• What happens if a model fails? (Is there a manual fallback?)
• How often are models retrained? (Monthly, quarterly, ad hoc?)
• Who owns model maintenance? (Is there a dedicated team, or is it ad hoc?)

In healthcare, deployment is slow and expensive. Integrating AI into an EHR requires HL7/FHIR expertise, security hardening, and clinical validation. If the target has built this infrastructure, that’s a moat. If they haven’t, you’re looking at 6–12 months of engineering post-acquisition to go live.

Pillar 5: Governance, Risk & Compliance

This is where healthcare AI diverges sharply from other sectors. You can’t just deploy an algorithm; you need governance. That means:

• A model risk management (MRM) framework that documents model purpose, training data, validation, and performance monitoring.
• Clinical governance: who approves model outputs? Who’s accountable if the model makes a bad decision?
• Regulatory readiness: if the model is a medical device (which many diagnostic models are), does the company understand FDA requirements?
• Audit trails: can you prove that a model was validated before deployment and monitored after?

Many healthcare companies have zero formal governance. They have a data scientist who built a model, and it’s running in production, but there’s no documentation, no approval process, no monitoring. That’s a ticking time bomb. You’ll need to build governance post-acquisition—and it’s not cheap or fast.

Check whether the target has read the NIST AI Risk Management Framework, which provides a structured approach to identifying and managing AI risks. Also ask about the WHO’s guidance on ethics and governance of AI for health, which is increasingly cited by regulators and health systems.

---

Technical Architecture & Regulatory Risk

Once you’ve assessed AI readiness, zoom in on technical architecture and regulatory exposure. This is where you separate defensible platforms from fragile prototypes.

Architecture Audit: Questions to Ask

Infrastructure & Scalability

Is the AI infrastructure cloud-native, containerised, and scalable? Or is it a monolithic system that will break under load? In healthcare, you often need to serve models to thousands of concurrent users (e.g., a diagnostic algorithm used across a hospital network). If the target’s infrastructure can’t scale, you’ll need to re-architect post-acquisition.

Also ask about data pipelines. How does data flow from source systems (EHR, labs, imaging) into the model? Is it real-time, batch, or ad hoc? In clinical applications, latency matters. A triage model that takes 30 seconds to run is useless in the ED. If the target’s pipelines are slow, you’ve found a value-creation opportunity: optimise the pipeline, improve clinical outcomes, and increase adoption.

Security & HIPAA Readiness

Healthcare data is the crown jewel. HIPAA violations cost millions in fines and destroy trust. During diligence, you need to understand:

• Is the infrastructure HIPAA-compliant? (Encrypted in transit and at rest, audit logs, access controls.)
• Are there penetration tests or security audits?
• How is data access controlled? (Role-based access control, principle of least privilege?)
• Is there encryption key management?
• How are data breaches detected and reported?

Many mid-market healthcare companies have basic HIPAA controls but no rigorous security programme. If you’re planning to acquire and scale, you’ll need to invest in security. Budget for SOC 2 Type II compliance, which is increasingly required by enterprise customers and health systems.

For regulated devices (diagnostic models, clinical decision support), there’s an additional layer: FDA oversight of software as a medical device. If the target’s AI is classified as a medical device, you need to understand the regulatory pathway. Is it Class I, II, or III? Has it been cleared/approved by the FDA, or is it still in development? If it hasn’t been cleared, what’s the timeline and cost to get there?

Regulatory Classification & Pathway

This is critical. Not all healthcare AI is regulated equally. A revenue cycle optimisation model might not be a medical device. A diagnostic imaging AI almost certainly is.

During diligence, work with a regulatory consultant to classify the target’s AI:

• Medical Device: Does the AI diagnose, treat, or monitor a disease? If yes, it’s likely a medical device and subject to FDA oversight.
• Clinical Decision Support: Does it provide recommendations to clinicians? If the clinician can easily override it, it might be exempt from FDA review (though this is evolving).
• Operational/Administrative: Does it optimise scheduling, billing, or inventory? Probably not a medical device.

For medical devices, the FDA has published guidance on AI/ML software, including requirements for validation, real-world performance monitoring, and algorithm changes. Understanding this pathway is essential to forecasting post-acquisition costs and timelines.

Interoperability & Data Exchange

Healthcare is moving toward interoperability. The 21st Century Cures Act requires health systems to share data via open standards (FHIR). If the target’s AI is locked into a single EHR or health system, it’s fragile. If it can ingest FHIR data and integrate with multiple EHRs, that’s a moat.

During diligence, ask:

• Can the AI ingest data from multiple EHRs?
• Is the data model standards-based (FHIR, HL7)?
• Can the output be consumed by downstream systems?
• Are there integrations with major EHRs (Epic, Cerner, Athena)?

If the answer to all of these is no, you’ll need to invest in interoperability post-acquisition. That’s a 6–12 month engineering effort, but it’s essential to scaling across multiple health systems.

---

Data Quality, Governance & Compliance

Data is the foundation of AI. In healthcare, data quality is often poor, and governance is ad hoc. This is where you find the biggest value-creation opportunities—and the biggest risks.

Data Quality Assessment

Completeness & Consistency

Start with the basics: what percentage of records are complete? In healthcare, missing data is endemic. Lab results might be missing because a test wasn’t ordered. Medication lists might be incomplete because patients filled prescriptions at multiple pharmacies. Diagnoses might be coded inconsistently across departments.

During diligence, sample the data. Pull 1,000 records at random and audit them:

• How many have missing values?
• Are there duplicates?
• Are dates consistent? (Can you have a discharge date before an admission date?)
• Are codes standardised? (Are diagnoses coded in ICD-10, or are there free-text entries?)

If more than 10–15% of data is missing or inconsistent, you’ve found a data quality problem. That will require data cleaning and governance investment post-acquisition.

Representativeness & Bias

AI models are only as good as the data they train on. If training data comes from a single health system with a specific patient population, the model will likely fail when deployed to other systems with different demographics.

During diligence, ask:

• What’s the demographic composition of the training data? (Age, gender, race/ethnicity, comorbidities.)
• Is it representative of the target patient population?
• Are there underrepresented groups?
• Has the model been tested on external data from other health systems?

For diagnostic models, external validation is essential. A radiology AI trained on 10,000 images from a single hospital might not work on images from a different vendor’s scanner. Ask whether the target has conducted external validation studies. Published results are a strong signal; internal-only validation is a red flag.

Data Governance & Lineage

In regulated healthcare, you need to know where data comes from, how it’s processed, and who has access. That’s data governance, and most healthcare companies have minimal governance.

During diligence, map the data estate:

• Where does data originate? (EHR, lab system, imaging archive, patient-generated devices.)
• How is it extracted and loaded? (ETL pipelines, APIs, manual exports.)
• Where is it stored? (Data warehouse, data lake, cloud storage.)
• Who has access? (Data scientists, analysts, engineers, clinicians.)
• How is access logged and audited?

If you can’t trace the lineage of a dataset, you can’t validate it. And if you can’t validate it, you can’t defend it in an audit or regulatory investigation.

Post-acquisition, you’ll likely need to implement a data governance programme. That means:

• A data catalogue documenting all datasets, their source, quality, and lineage.
• Access controls tied to job function and need-to-know.
• Audit logs for all data access.
• Data quality metrics and monitoring.

This is not a one-time project; it’s an ongoing function. Budget for a data governance lead and supporting tools (data cataloguing, lineage tracking, access management).

Compliance: HIPAA, State Privacy Laws & GDPR

Healthcare data is subject to HIPAA, state privacy laws (CCPA, HIPAA Omnibus Rule), and if the company operates internationally, GDPR. During diligence, you need to understand compliance posture.

HIPAA

HIPAA sets the baseline for healthcare data protection in the US. It requires:

• Encryption of PHI (Protected Health Information) in transit and at rest.
• Access controls and audit logs.
• Incident response and breach notification procedures.
• Business associate agreements (BAAs) with vendors.

Ask the target:

• Have you conducted a HIPAA risk assessment?
• Are all systems using HIPAA-compliant vendors?
• Do you have BAAs with all vendors handling PHI?
• Have you had a HIPAA audit?

If the answer to any of these is no, you’ve found a compliance gap. Budget for a HIPAA audit and remediation post-acquisition.

State Privacy Laws

Many states now have privacy laws (CCPA in California, HIPAA Omnibus in Colorado, etc.). These require companies to disclose data practices, allow consumers to access and delete their data, and implement safeguards. If the target operates in multiple states, compliance gets complex.

During diligence, ask whether the target has mapped its operations to state privacy requirements and implemented necessary controls.

GDPR

If the target processes data on EU residents, GDPR applies. GDPR is stricter than HIPAA: it requires explicit consent for data processing, gives individuals broad rights (access, deletion, portability), and imposes significant fines for violations. If the target has EU customers or patients, you need GDPR-ready architecture and processes.

For companies pursuing SOC 2 Type II compliance, this often includes GDPR readiness as part of the broader security and privacy audit.

---

Model Risk Management & Validation

Healthcare AI models carry clinical risk. A wrong diagnosis can harm a patient. A flawed risk prediction can lead to inappropriate treatment. That’s why model risk management (MRM) is essential.

The Model Risk Management Framework

MRM is a structured approach to identifying, measuring, and managing risks in AI models. It includes:

Model Development & Validation

Models should be developed using rigorous methodology:

• Clear problem definition and success criteria.
• Appropriate algorithm selection and hyperparameter tuning.
• Proper train/test/validation split (ideally with external validation on held-out data).
• Cross-validation to assess generalisability.
• Sensitivity analysis to understand how model performance varies with input changes.

During diligence, ask to see model development documentation. Is there a clear record of algorithm selection, hyperparameter choices, and validation results? Or is it just a notebook with some code?

Model Validation & Testing

Before deployment, models should be validated:

• Clinical validation: Does the model perform well on real patient data? Have clinicians reviewed the model’s outputs and validated them against their clinical judgment?
• Fairness & bias testing: Does the model perform equally well across demographic groups?
• Stress testing: How does the model perform on edge cases, rare conditions, or unusual presentations?
• Adversarial testing: Can the model be fooled by adversarial inputs?

For diagnostic models, external validation is critical. A model trained on data from Hospital A might not work on data from Hospital B. Ask whether the target has conducted external validation studies, ideally published in peer-reviewed journals.

Performance Monitoring & Drift Detection

Once deployed, models need to be monitored. Model performance can degrade over time due to:

• Data drift: The distribution of input data changes (e.g., patient demographics shift, disease prevalence changes).
• Concept drift: The relationship between inputs and outputs changes (e.g., treatment guidelines evolve, clinical practices shift).
• Model drift: The model’s performance degrades even if the data distribution is stable (e.g., due to software bugs or infrastructure changes).

During diligence, ask:

• How is model performance monitored in production?
• Are there alerts if performance degrades?
• How often are models retrained?
• Is there a process to detect and respond to data drift?

If the answer is “we don’t really monitor,” you’ve found a major gap. Post-acquisition, you’ll need to implement monitoring and retraining pipelines. This is not optional in healthcare.

Validation for Regulated Devices

If the target’s AI is classified as a medical device, validation requirements are more stringent. The FDA expects:

• Analytical validation: Does the model accurately identify the target (e.g., disease, risk factor)?
• Clinical validation: Does the model’s output lead to improved clinical outcomes?
• Real-world performance monitoring: Does the model perform as expected when deployed to clinical practice?

For AI/ML devices, the FDA’s guidance emphasises the need for a robust validation strategy and post-market surveillance plan. If the target hasn’t conducted this level of validation, you’re looking at significant post-acquisition investment to achieve regulatory compliance.

Benchmarking Model Performance

During diligence, you need to understand model performance in concrete terms:

• Sensitivity & specificity: For diagnostic models, what’s the true positive rate and false positive rate?
• Positive predictive value (PPV) & negative predictive value (NPV): If the model predicts positive, how likely is it correct? (This is often more clinically relevant than sensitivity/specificity.)
• Area under the curve (AUC): A summary metric of model discrimination across all thresholds.
• Calibration: Are predicted probabilities accurate? (If the model predicts 70% risk, does the outcome occur 70% of the time?)

Benchmark these against existing clinical standards or published results. A diagnostic model with 85% sensitivity might sound good, but if the existing standard is 92%, it’s not competitive.

Also ask: what’s the clinical relevance of model performance? A small improvement in AUC might not translate to better patient outcomes. Conversely, a seemingly modest improvement might have substantial clinical impact if it reduces unnecessary procedures or speeds diagnosis.

---

Team, Hiring & Capability Gaps

AI is only as good as the team building it. During diligence, you need to assess technical depth, clinical expertise, and whether the team can scale post-acquisition.

Technical Talent Assessment

Data Science & ML Engineering

Ask:

• How many data scientists and ML engineers does the target have?
• What’s their background? (PhDs in ML, industry experience, or self-taught?)
• Have they published papers or contributed to open-source projects?
• What’s the ratio of data scientists to engineers? (Ideally, you want more engineers than scientists; scientists are common, engineers are scarce.)
• Are they building models, or are they building the infrastructure to support models at scale?

Red flags:

• Only one data scientist (key person risk).
• No ML engineers (models won’t scale).
• All PhDs with no industry experience (might build elegant models that don’t work in production).
• High turnover (suggests the team is burning out or being poached).

Clinical & Domain Expertise

Healthcare AI requires domain expertise. Someone needs to understand the clinical problem, the data, and the regulatory landscape. That person might be a clinician (MD, RN, pharmacist) or a domain expert with deep healthcare experience.

Ask:

• Does the team include clinicians or domain experts?
• Are they involved in model development, or just as advisors?
• Do they have relationships with health systems for validation and deployment?
• Are they clinical co-founders, or hired post-seed?

Red flags:

• No clinical expertise on the founding team.
• Clinicians hired as advisors but not involved in product decisions.
• No relationships with health systems (hard to validate and deploy without them).

Product & Engineering Leadership

You need a strong head of product and head of engineering to scale. Ask:

• Who’s the head of product? Do they understand healthcare, regulatory requirements, and customer needs?
• Who’s the head of engineering? Can they build scalable, secure, HIPAA-compliant infrastructure?
• Have they scaled teams before? (Scaling from 5 to 50 engineers is different from scaling from 1 to 5.)
• Are they building for the right customer (e.g., health systems, not individual clinicians)?

Hiring & Capability Gaps

No team is complete. During diligence, identify gaps:

Fractional CTO / Technical Leadership

Many mid-market healthcare companies lack senior technical leadership. If the target doesn’t have a CTO or VP of Engineering, that’s a gap. Post-acquisition, you might need to hire or bring in fractional leadership to set technical direction, build the team, and ensure regulatory compliance.

PADISO offers fractional CTO and CTO advisory services across multiple geographies, including Boston, San Francisco, and New York, which can be valuable for healthcare companies scaling their technical leadership.

Platform Engineering & Infrastructure

Many healthcare companies have strong data science but weak platform engineering. If the target lacks infrastructure expertise (cloud architecture, databases, observability, security), you’ll need to hire or partner with platform engineers post-acquisition.

Platform engineering services in healthcare hubs can accelerate infrastructure modernisation, especially for HIPAA-compliant data platforms and clinical integrations.

Security & Compliance

If the target lacks security expertise, you’ll need to hire or partner with a security team to achieve SOC 2 / ISO 27001 compliance and prepare for regulatory audits. This is non-negotiable in healthcare.

Clinical Affairs & Regulatory

If the target’s AI is a medical device, you need clinical affairs and regulatory expertise. This might be a hire or a partner (consulting firm, regulatory agency). Budget for this early.

Retention & Key Person Risk

During diligence, identify key people. If the AI strategy depends on one person, that’s a risk. Post-acquisition, you need to:

• Understand key person dependencies.
• Negotiate retention bonuses for critical team members.
• Document knowledge (models, data pipelines, customer relationships).
• Plan for backfill and succession.

In healthcare tech, retention is often harder than in consumer tech. Clinicians might be tempted to return to clinical practice. Data scientists might be recruited by larger tech companies. Budget for competitive compensation and a strong engineering culture to retain talent.

---

Value-Creation Roadmap: 100-Day Plan

Once you’ve completed diligence and closed the deal, you need a value-creation plan. Here’s a 100-day roadmap focused on AI and technology.

Days 1–30: Stabilise & Assess

Week 1–2: Onboarding & Knowledge Transfer

• Meet the team. Understand their strengths, gaps, and concerns.
• Document the current state: what AI models are in production? What’s in development? What’s been abandoned?
• Understand the customer base: who’s using the AI? How? What’s the feedback?
• Identify key dependencies: what would break if a person left? What would break if a system went down?

Week 3–4: Technical Audit

• Conduct a technical architecture review. Is the infrastructure scalable, secure, and maintainable?
• Audit AI models in production. Are they validated? Monitored? Documented?
• Assess data quality and governance. Are there data lineage, access controls, and audit logs?
• Identify technical debt. What needs to be refactored or rebuilt?

Post-acquisition, a platform engineering partner can accelerate this assessment, especially for healthcare-specific concerns like HIPAA compliance and clinical integrations.

Days 31–60: Roadmap & Quick Wins

Identify Quick Wins

Quick wins build momentum and demonstrate value. Look for:

• Operational efficiency: Can you optimise a data pipeline to reduce latency? Can you automate a manual process? Can you reduce cloud costs?
• Model improvements: Are there low-hanging fruit to improve model accuracy or reduce false positives?
• Customer success: Are there customer requests that are easy to implement and high-impact?
• Compliance: Are there compliance gaps that are easy to close (e.g., implementing audit logging)?

Target 2–3 quick wins in the first 60 days. Quantify the impact: time saved, cost reduction, accuracy improvement, customer satisfaction.

Build the 12-Month Roadmap

Work with the team to build a realistic 12-month roadmap:

• Product roadmap: What new AI models or features will be built? What’s the priority? What’s the timeline?
• Technology roadmap: What infrastructure, tools, or platforms need to be upgraded or built?
• Compliance roadmap: What audits or certifications need to be achieved? (SOC 2, ISO 27001, FDA clearance if applicable.)
• Team roadmap: What hiring is needed? What skill gaps need to be filled?
• Revenue roadmap: How will AI drive revenue growth? New customers? Expansion within existing customers? New use cases?

Be realistic. Healthcare projects move slowly. If you’re planning FDA clearance, expect 12–24 months. If you’re pursuing SOC 2 compliance, budget 3–6 months.

Days 61–100: Execution & Momentum

Execute Quick Wins

Deliver on the quick wins identified in weeks 3–4. This builds credibility with the team and demonstrates value to stakeholders.

Establish Governance & Processes

Healthcare requires governance. Establish:

• Model governance: Who approves new models? How are they validated? How is performance monitored?
• Data governance: Who owns data? How is access controlled? How is quality assured?
• Security governance: Who’s responsible for security? How are incidents handled? How is compliance tracked?
• Clinical governance: Who approves clinical decisions? How is patient safety ensured?

These don’t need to be heavy-weight processes, but they need to exist and be documented.

Secure Key Hires

If you’ve identified capability gaps, start recruiting. For healthcare, key hires include:

• Head of Platform Engineering (if not in place).
• Security Lead or Chief Information Security Officer (CISO).
• Clinical Affairs Lead (if pursuing FDA clearance).
• Data Governance Lead.

For fractional leadership, consider CTO advisory services to bridge gaps while you recruit full-time talent.

Communicate the Vision

Create a compelling narrative for the team, customers, and investors:

• What’s the vision for AI in this company? (Not “we’ll use more ML,” but “we’ll reduce diagnostic time by 50% and improve accuracy by 20%.”)
• What’s the competitive moat? (Is it proprietary data, superior algorithms, clinical relationships, or something else?)
• What’s the path to value? (How does AI drive revenue, reduce costs, or improve outcomes?)
• What’s the timeline? (When will the next milestone be achieved?)

Communicate clearly and often. Update the team weekly, customers monthly, and investors quarterly.

---

Exit Positioning: AI as a Moat

When you’re ready to exit—whether to a strategic buyer, IPO, or secondary—AI needs to be a moat, not a liability. Here’s how to position it.

The AI Narrative for Buyers

Strategic buyers (large health systems, health IT vendors, pharmaceutical companies) are looking for AI that:

1. Drives revenue or reduces costs: Quantify the impact. “Our AI reduces diagnostic time by 40%, allowing radiologists to see 30% more patients, generating $5M annual incremental revenue per hospital.”

2. Is defensible: Do you have proprietary data, algorithms, or relationships that competitors can’t easily replicate? Emphasise data moats (longitudinal patient data, multi-site validation) and clinical relationships.

3. Is compliant & validated: Buyers want to acquire assets, not liabilities. Having SOC 2, ISO 27001, and (if applicable) FDA clearance dramatically increases valuation. Show rigorous validation and real-world performance data.

4. Scales: Buyers want to deploy your AI across their entire customer base. Show that the AI generalises across different health systems, patient populations, and use cases. External validation data is critical.

5. Is governed & maintainable: Show that you have model governance, data governance, and security governance in place. Buyers want to acquire a mature, scalable operation, not a fragile prototype.

Valuation Multiples for AI-Driven Healthcare

AI-driven healthcare companies command premium valuations. Based on recent M&A data:

• Diagnostic AI companies: 8–15x revenue (vs. 3–5x for non-AI health IT).
• Clinical decision support: 6–12x revenue.
• Operational/administrative AI: 4–8x revenue.

The premium depends on:

• Validation: Published clinical validation studies add 20–30% premium.
• Compliance: SOC 2 / ISO 27001 adds 10–15% premium. FDA clearance adds 30–50%.
• Scalability: Demonstrating deployment across multiple health systems adds 20–30%.
• Team: Retaining key technical and clinical talent adds 10–20%.

To maximise exit value, focus on:

1. Clinical validation: Publish results in peer-reviewed journals. This is expensive and time-consuming, but it’s worth millions at exit.

2. Compliance: Achieve SOC 2 Type II and ISO 27001 before you approach buyers. It signals maturity and reduces buyer risk.

3. Real-world performance: Show that your AI works in production, not just in studies. Collect real-world performance data from deployed customers.

4. Expansion data: Show that the AI generalises. If you’ve validated in 5 health systems and are expanding to 10, that’s a strong signal of scalability.

5. Regulatory pathway: If applicable, map the path to FDA clearance and show progress. Even if you haven’t achieved clearance yet, showing a clear roadmap adds value.

Red Flags That Kill Valuation

Buyers will discount valuation (or walk away) if they see:

• Unvalidated models: Models that haven’t been clinically validated or externally tested.
• Key person dependency: If the AI strategy depends on one person, that’s a valuation killer.
• Poor governance: No model governance, no data governance, no security controls.
• Regulatory uncertainty: If there’s uncertainty about whether the AI is a medical device, or what the regulatory pathway is.
• Limited scalability: If the AI only works in one health system or on one type of data.
• High technical debt: Infrastructure that’s fragile, hard to maintain, or not scalable.

---

Red Flags & Deal-Breakers

During diligence, watch for red flags that indicate deeper problems.

Technical Red Flags

• No version control: Code isn’t in Git. Models aren’t versioned. This indicates an immature engineering practice.
• No testing: There are no unit tests, integration tests, or validation tests. This is a sign of poor software engineering.
• No monitoring: Models are in production but not monitored. If performance degrades, nobody will know.
• High technical debt: Code is unmaintainable. Infrastructure is fragile. Refactoring is deferred.
• Poor documentation: There’s no documentation of models, data, or architecture. Knowledge is tribal.
• Security is an afterthought: No encryption, no access controls, no audit logs. This is a compliance disaster waiting to happen.

Data Red Flags

• Single-source data: All training data comes from one health system. The model likely won’t generalise.
• No external validation: Models have only been tested on internal data. External validation is essential.
• High missing data: More than 15–20% of records have missing values. This indicates data quality problems.
• Demographic imbalance: Training data is skewed toward one demographic group. The model likely has bias.
• No data governance: Nobody knows where data comes from, how it’s used, or who has access.
• No audit trail: Data access isn’t logged. You can’t prove compliance.

Team Red Flags

• No clinical expertise: The team has no doctors, nurses, or healthcare domain experts. They don’t understand the clinical problem.
• High turnover: Key people are leaving. This indicates a cultural or compensation problem.
• Key person dependency: If the lead data scientist leaves, the entire AI strategy collapses.
• No product/engineering leadership: There’s no head of product or head of engineering. The team is flying blind.
• Weak hiring: The team can’t recruit talent. This indicates a culture or compensation problem.

Regulatory Red Flags

• No compliance programme: The company has never had a HIPAA audit or security assessment.
• Unclear regulatory status: Nobody knows whether the AI is a medical device or what the FDA pathway is.
• No governance framework: There’s no model governance, no data governance, no security governance.
• Unresolved compliance gaps: There are known HIPAA violations or security issues that haven’t been addressed.
• No audit trail: You can’t prove that models were validated or that data access is controlled.

Deal-Breaker Checklist

Walk away if:

• There’s no clear clinical validation of the AI model.
• The team has no healthcare domain expertise.
• There are known HIPAA violations or security breaches.
• The AI is classified as a medical device but hasn’t been validated for regulatory clearance, and the company has no plan to achieve it.
• The entire AI strategy depends on one person.
• The company has no data governance and can’t explain where data comes from.
• There’s active litigation or regulatory investigation.

---

Next Steps & Implementation

You’ve now got a comprehensive framework for AI due diligence in healthcare. Here’s how to implement it.

Pre-Diligence: Build Your Diligence Team

You’ll need:

• Technical lead: Someone who can audit architecture, data, and models. This could be an internal CTO, a fractional CTO, or a consulting partner.
• Clinical advisor: A clinician or healthcare domain expert who can assess clinical validity and regulatory risk.
• Regulatory advisor: Someone who understands FDA, HIPAA, and state privacy laws.
• Security advisor: Someone who can assess HIPAA compliance and security posture.

For technical leadership, consider engaging a fractional CTO service with healthcare expertise. PADISO has deep experience in healthcare tech due diligence and can lead technical audits across multiple regions.

During Diligence: Execute the Framework

1. Week 1: Conduct the AI Readiness Assessment (Section 2). Score the target on the five pillars.

2. Week 2: Deep-dive on technical architecture and regulatory risk (Section 3). Understand the regulatory pathway and architecture scalability.

3. Week 3: Audit data quality and governance (Section 4). Sample the data. Understand compliance posture.

4. Week 4: Assess model risk management and validation (Section 5). Review model development and validation studies.

5. Week 4: Evaluate the team (Section 6). Identify capability gaps and key person risks.

6. Week 5: Synthesise findings and build the value-creation roadmap.

Post-Close: Execute the Value-Creation Plan

1. Days 1–30: Stabilise. Understand the current state. Identify key dependencies.

2. Days 31–60: Plan. Build the 12-month roadmap. Identify quick wins.

3. Days 61–100: Execute. Deliver quick wins. Establish governance. Secure key hires.

For platform engineering support during post-acquisition integration, PADISO can help scale infrastructure, achieve compliance, and modernise architecture across geographies.

Ongoing: Compliance & Governance

Post-acquisition, you’ll need ongoing compliance and governance:

• Security audits: Conduct annual security assessments and work toward SOC 2 Type II compliance.
• Model governance: Establish and maintain a model governance framework.
• Data governance: Implement data lineage, quality monitoring, and access controls.
• Clinical governance: If applicable, establish clinical affairs and regulatory functions.
• Team development: Invest in hiring and developing technical talent.

Tools & Resources

To support your diligence and post-acquisition work:

• AI Risk Management: Refer to the NIST AI Risk Management Framework for a structured approach to identifying and managing AI risks.
• Healthcare AI Governance: Review the WHO’s guidance on ethics and governance of AI for health for international best practices.
• Clinical AI Implementation: Read the peer-reviewed literature on clinical AI implementation and governance for evidence-based practices.
• Regulatory Guidance: Review the FDA’s guidance on AI/ML software as a medical device if the target’s AI is a medical device.
• HIPAA & Health IT: Refer to HHS resources on HIPAA and health IT for compliance requirements.
• Industry Benchmarks: Review McKinsey’s analysis of AI in healthcare for market context and use case validation.
• ISO AI Risk Management: Reference ISO/IEC 23894:2023 on AI risk management for international standards.
• OECD AI Principles: Review the OECD AI Principles as a benchmark for governance and responsible deployment.

Getting Help

If you need hands-on support:

• Technical diligence: Engage a fractional CTO with healthcare experience to lead technical audits and build value-creation roadmaps.
• Platform engineering: Partner with platform engineering specialists to modernise infrastructure and achieve compliance post-acquisition.
• Security & compliance: Work with a security audit partner to achieve SOC 2 / ISO 27001 compliance and prepare for regulatory audits.
• AI strategy & architecture: Engage AI advisory services to validate AI strategy, assess model risk, and plan AI roadmaps.

PADISO has worked with dozens of healthcare companies on due diligence, post-acquisition integration, and AI value creation. We can help you avoid the pitfalls and accelerate value creation.

---

Conclusion

AI due diligence in healthcare is complex. It requires technical depth, clinical expertise, regulatory knowledge, and operational rigour. But the stakes are high: healthcare AI companies command premium valuations, and the value-creation opportunities are substantial.

Use this framework to:

1. Assess AI readiness across five pillars: strategy, data, model development, deployment, and governance.
2. Understand technical and regulatory risk by auditing architecture, compliance, and regulatory classification.
3. Evaluate data quality and governance by sampling data, assessing lineage, and understanding compliance posture.
4. Assess model risk by reviewing validation, testing, and monitoring practices.
5. Evaluate the team and identify capability gaps and retention risks.
6. Build a value-creation roadmap focused on quick wins, governance, and scaling.
7. Position for exit by emphasising clinical validation, compliance, and scalability.

Don’t cut corners on diligence. A thorough assessment now will save millions in post-acquisition surprises and unlock substantial value creation.

Ready to dive deeper? Engage a technical partner to lead your diligence, and build a value-creation plan before you close the deal.